Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and HIFU in Metastatic Breast Cancer
NCT03237572Phase 1Terminated
- Start
- Sep 2017
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in breast cancer (2 arms). Primary endpoint: Change in Proportion of CD8+ Tumor Infiltrating Lymphocytes at 4 weeks. Started Sep 2017; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03237572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237572.